New app aims to keep patients on Weight-Loss drugs longer
NCT ID NCT07216651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a web-based tool called WeDosify that helps doctors manage dosing of the weight-loss drug semaglutide for adults with overweight or obesity. Twenty participants who had recently started semaglutide used the tool over three months. The main goal was to see how many people stayed on the medication without stopping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amarillo Premier Research (an Objective Health Partnership)
Amarillo, Texas, 37067, United States